Teplizumab For Diabetes Episode 315 – Real Life Pharmacology Podcast
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist
4.9 • 773 Ratings
🗓️ 22 February 2024
⏱️ 16 minutes
🧾️ Download transcript
Summary
Teplizumab is a relatively new agent that helps delay the progression of type 1 diabetes. It slows the rate of beta-cell destruction in the pancreas.
Teplizumab is associated with cytokine release syndrome which can result in flu-like symptoms of fever, aches, and headache.
Cytokine release syndrome due to teplizumab can be reduced by using appropriate pretreatment medications. Those medications can include analgesics, antihistamines, and/or antiemetics.
Teplizumab is associated with suppressing the immune system so it is ideal to get vaccinations completed before using this medication. I go over the specific recommendations in the podcast episode.
Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE!
Support The Podcast and Check Out These Amazing Resources!
Meded101 Guide to Nursing Pharmacology (Amazon Highly Rated)
Guide to Drug Food Interactions (Amazon Best Seller)
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Hey all, welcome back to the Real Life Pharmacology podcast. |
| 0:03.4 | I'm your host pharmacist, Eric Christensen. |
| 0:05.5 | Thank you so much for listening today. |
| 0:08.2 | Go check out Real Life Pharmacology.com. |
| 0:11.0 | We've got your free 31-page PDF on the top 200 drugs. |
| 0:15.5 | Great study guide and refresher to have, no matter who you are. |
| 0:18.9 | If you're in pharmacy school, nursing school, |
| 0:22.1 | med school, taking pharmacology classes, you know, recently out in practice, need a little |
| 0:27.8 | refresher on things. Simply an email will get you access to that. So definitely go take advantage |
| 0:33.8 | of that where I lay out some of the most important clinical practice |
| 0:37.7 | pearls on the top 200 drugs. All right, let's get into the drug of the day today and |
| 0:43.6 | this is by request. It is to plizumab. So this is probably a fairly rare drug that you're |
| 0:53.4 | going to see used in your clinical practice. |
| 0:57.3 | If you work in diabetes, you're probably more likely to be able to see it here. |
| 1:02.8 | Brand name of this medication is T-Zield, and it is a monoclonal antibody and it is classified as an anti-CD3 antibody. |
| 1:19.8 | So mechanistically, what this medication does is it delays the onset of stage three type 1 diabetes. So it's typically given in |
| 1:33.6 | patients who have stage 2 type 1 diabetes. So this medication binds CD3, which CD3 is a cell surface antigen, |
| 1:50.6 | and those specific cells that that antigen is on, |
| 1:55.8 | that that CD3 antigen is on, is T cells. And more more specifically CD4 and CD8 T cells. Now what's important about these |
| 2:09.0 | T cells? So remember this is part of the immune system basically and if you remember |
| 2:15.0 | killer T cells from maybe some of your biology classes and things of that nature, |
| 2:22.0 | these are part of the immune system that destroy things, basically. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.